first month on tirzepatide Wrapping Up My – Weekly Accountability Post : r/tirzepatidecompound How Much Do You Lose

MK-0616, an oral macrocyclic peptide PCSK9 inhibitor developed by Merck, demonstrated robust LDL-C reductions of up to 60.9% in Phase 2b trials and is now under NDA review ( The historical record, therefore, offers a clear but frequently ignored lesson

I can't do it alone

Sorbitol, xylitol, erythritol, and maltitol are poorly absorbed in the small intestine

Patients with cardiovascular disease, chronic kidney disease, or other obesity-related complications may benefit from extended treatment, though cardiovascular and renal outcome trials with tirzepatide are still ongoing, and definitive risk reduction benefits remain under investigation

That accessibility carries real value, even if it is hard to quantify in dollars